Somatic mutations predict prognosis in myelodysplastic syndrome patients with normal karyotypes  

作　　者：Xiangzong Zeng Yu Zhang Ke Zhao Lingling Zhou Ya Zhou Li Xuan Rui Cao Jun Xu Min Dai Qifa Liu 

机构地区：[1]Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第8期2319-2321,共3页信号转导与靶向治疗（英文）

基　　金：This work was supported by the National Key Research and Development Projects(Grant Nos.2017YFA0105500,2017YFA105504);the National Natural Science Foundation of China(Grant Nos.81770190,81970161,81500149);R&D projects in key areas of Guangdong Province(Grant No.2019B020236004).

摘　　要：Dear Editor,Myelodysplastic syndromes(MDSs)are a group of clonal myeloid stem cell disorders characterized by varying degrees of cytopenias,cytogenetic and molecular genetic abnormalities,and a predisposition to acute myeloid leukemia(AML).The treatments for MDS mainly consist of cytoreductive treatment,such as traditional AML-like chemotherapy,hypomethylating agents(HMAs),allogeneic hematopoietic stem cell transplantation(alio-HSCT)and immunoregulation according to risk stratification.

关 键 词：DYSPLASTIC CHEMOTHERAPY MYELOID 

分 类 号：R551.3[医药卫生—血液循环系统疾病]